Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Category | Sectoral / Thematic | Sectoral / Thematic |
| Plan | Direct | Direct |
| Fund house | Nippon India | Axis |
| NAV | ₹666.3420 | ₹22.8900 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 13.9 years | 6.8 years |
| Expense ratio | 1.0% | 1.8% |
| Stars | ★★★★★ | ★★★★★ |
| Growth Score | 75.20 | 27.80 |
Returns
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| 1 month | +11.40% | +6.66% |
| 3 months | +3.74% | −0.17% |
| 6 months | +8.55% | +4.33% |
| YTD | +16.94% | −3.13% |
| 1 year | +15.26% | −3.09% |
| 3 years (CAGR) | +17.96% | +8.47% |
| 5 years (CAGR) | +15.40% | +5.41% |
| 10 years (CAGR) | +16.61% | — |
| Since launch | +17.63% | +12.87% |
Risk
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Volatility | 14.1% | 14.1% |
| Downside volatility | 9.0% | 10.3% |
| Sharpe | 0.81 | 0.14 |
| Sortino | 1.28 | 0.19 |
| Calmar | 1.22 | 0.48 |
| Return / risk | 1.27 | 0.60 |
| Deepest fall | −24.02% | −24.30% |
| Days to recover | 445 | 517 |
| Below its high | +0.00% | −7.66% |
Against benchmark
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Alpha | −1.86% | — |
| Beta | 0.89 | — |
| R² | 89.5% | — |
| Up capture | 85.2% | — |
| Down capture | 88.7% | — |
| Tracking error | 4.8% | — |
| Information ratio | −0.69 | — |
| Treynor | 0.12 | — |
Consistency
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Best 1-year | +90.70% | +70.80% |
| Middle 1-year | +13.13% | +9.41% |
| Worst 1-year | −15.12% | −16.36% |
| 1-year periods with a loss | 23.2% | 28.8% |
| Middle 3-year | +19.82% | +13.11% |
| Positive months | 63.9% | 63.9% |
| Best day | +3.40% | +3.71% |
| Worst day | −3.21% | −3.53% |
| Worst 5% day | −1.38% | −1.22% |
| Positive days | 53.7% | 52.6% |
| NAVs a year | 247 | 251 |
SIP of ₹10,000 a month
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| 5-year XIRR | +18.24% | +7.32% |
| 5-year value | ₹9,54,076 | ₹7,24,420 |
| 3-year XIRR | +14.26% | +3.16% |
| 1-year XIRR | +22.08% | +2.79% |
Holdings overlap i
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Nippon India Pharma Fund | — | 8% |
| Axis ESG Integration Strategy Fund | 8% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Held by all of them
| Stock | Nippon India Pharma Fund | Axis ESG Integration Strategy Fund |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.55% | 2.77% |
| IPCA Laboratories Limited | 2.90% | 1.35% |
| Anthem Biosciences Limited | 1.30% | 1.67% |
| Biocon Limited | 0.97% | 2.29% |
| Alkem Laboratories Limited | 1.82% | 0.73% |
| Gland Pharma Limited | 2.73% | 0.39% |
Sectors and company size
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Large companies | 29.6% | 49.8% |
| Mid companies | 40.8% | 13.1% |
| Small companies | 28.7% | 21.2% |
| Top 10 holdings | 57.2% | 49.5% |
| Largest sector | Pharmaceuticals & Biotechnology 75% | Finance 13% |